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The development of new drugs is determined
largely by their ADME properties of which metabo-
lism is an important factor affecting e.g., bioavail-
ability, detoxification, drug-drug interactions and
individual pharmacokinetics and pharmacodynam-
ics variability. Drugs and xenobiotics are mainly
metabolized by different oxidation and conjugation
enzymes to more polar and better soluble metabo-
lites to facilitate their excretion (1).
Cytochrome P450 system represents drug-
metabolizing enzymes from a superfamily of hemo-
proteins, engaged in phase I metabolism. Among the
CYP isoforms, family 1 to 4 are involved in metab-
olism of different xenobiotics, and in human more
than 90% of drugs that undergo biotransformation
are metabolized by CYP 1A2, 2A6, 2B6, 2C9,
2C19, 2D6, 2E1 and 3A4 (2, 3). In the development
of new chemical entity, drug candidate, preclinical
screening of metabolism rates and assessment of
elimination routes are considered to be essential for
further development. 
In the field of drug discovery, a demand has
risen for efficient and rapid drug metabolism screen-
ing techniques. To speed up the selection of new
drug candidates, to identify the metabolic profile of
new molecules, to indicate likely drug interactions
or to assess the role of polymorphic enzymes, dif-
ferent in vitro systems have been developed.
LC/MS/MS technique provides a powerful
solution for investigating the biotransformation of
xenobiotics and is used at various stages of drug dis-
covery and development (4). Because of the need to
test a large number of compounds, recently a high-
throughput screening methods were created. One of
the application includes the use of the cocktail of
substrates added to the microsomal incubations for
simultaneous evaluation of the activities of CYP450
isoenzymes (5). Due to this approach multiple
enzymes may be assessed in the same study and the
effect of intra-individual variability is minimized.
Recently, numerous of drug metabolism cocktails
have been proposed and developed (6ñ15).
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Abstract: A sensitive and specific liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for
simultaneous determination of seven metabolites of CYP450 model substrates (acetaminophen, 4-hydroxy-
tolbutamide, 4í-hydroxymephenytoin, 1-hydroxybufuralol, 6-hydroxychlorzoxazone, 1í- and 4í-hydroxymida-
zolam) in rat liver microsomes was developed. The assay used Kinetex analytical column and a gradient mobile
phase consistent of acetonitrile and water with addition of 0.1% formic acid. The analysis was performed in
selected reaction monitoring (SRM) mode both in positive and negative (for 6-hydroxychlorzoxazone) mode.
The method was validated over the concentration ranges of 10-2000 ng/mL for 4í-hydroxymephenytoin and 4-
hydroxytolbutamide, 50-2000 ng/mL for 1-hydroxybufuralol and 25-2000 ng/mL for the rest of the analytes.
The intra- and inter-day precision (2-12%) and accuracy (93-119%) were within the limits set by the FDA and
EMA guidelines. The developed method was successfully applied to assess the activity of selected CYP450
isoenzymes in rat liver microsomes after addition of ketoconazole. 
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According to FDA guidelines, preclinical
metabolism studies of new drug candidates should
be conducted using human microsomes (16), while
there are numerous in vitro works for the assessment
of preliminary metabolic pathway of new com-
pounds using rat liver microsomes, cytosol and pri-
mary hepatocytes, because rats are the most com-
monly used model in the field of preclinical studies
(17ñ20). Among the frequent examples, work of
Xiao Hu et al. (21) demonstrated the variance analy-
sis of Vmax, Km and Clint values from the study of
enzyme kinetics of osthole and imperatorin, and
showed no significant difference between these val-
ues in rat and human liver microsomes. The study
demonstrated that the rat liver microsomes were
reliable to analyze drug metabolism in vitro. The
study of De Bock et al. (22) described the validation
of the method for determination of metabolites of
model substrates in rat microsomal matrix using ear-
lier derivatization of metabolites. The metabolic fate
of sublethal exposure of different herbicides in rat
microsomes was studied in the work of Larsen et al.
(23). On the basis of the results of Xue-Jin Zhao et
al. (24) one may assume that from a qualitative point
of view, the dog, rat and even mouse could be an
appropriate species for conducting an in vitro study
on the metabolism of quinine. However, using
rodent data to estimate human risk should be aware
of interspecies variability both in expression and
catalytic activity of relevant CYP450 isoforms (25).
The present study aims to evaluate a simple
and an accurate LC/MS/MS method for simultane-
ous determination of specific metabolites of six
model substrates metabolized by CYP450 isoen-
zymes after incubation with rat liver microsomes. In
the next step, the optimized method was used to
establish the strength of enzyme inhibition by keto-




MZ), 4í-hydroxymidazolam (4-OH-MZ), phena-
cetin, acetaminophen (ACP), tolbutamide, 4-
hydroxytolbutamide (4-OH-TB), bufuralol, 1-
hydroxybufuralol (1-OH-BF), S-mephenytoin, 4í-
hydroxymephenytoin (4-OH-MP), chlorzoxazone,
6-hydroxychlorzoxazone (6-OH-CH), dextrophan,
magnesium chloride, NADPH, Folin & Ciocalteuís
phenol reagent, potassium sodium tartrate tetrahy-
drate, cooper sulfate, sucrose, TRIS, sodium phos-
phate dibasic and potassium chloride were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA).
Formic acid was obtained from Fluka (Buchs,
Switzerland). Potassium dihydrogen phosphate,
sodium chloride, acetone and acetonitrile were pur-
chased from J.T. Baker (Phillipsburg, PA, USA).
Purified water (18.2 MΩ) used throughout the study
was delivered by a Milli-Q water system (Millipore,
Billerica MA, USA).
Isolation of hepatic microsomes 
Rat liver microsomes were prepared using a
differrential centrifugation method. Liver fragments
were minced with scissors, washed with TRIS/KCl
(pH 7.4) buffer and homogenized. The homogenate
was centrifuged (Sorval WX Ultra Series, Thermo
Scientific) at approximately 11 500 ◊ g for 20 min
at 4OC. The supernatant (S9 fraction) was transferred
to new centrifuge tubes and then ultracentrifuged at
100 000 ◊ g for 60 min at 4OC. The pellet was resus-
pended in 0.15 M KCl with Ultra Turrax IKA T10
basic homogenizer (IKA-Werke GmbH & Co. KG
Staufen, Germany) and ultracentrifuged again at 100
000 ◊ g for 60 min at 4OC. The obtained pellet was
dispersed in TRIS/sucrose buffer and stored at 
-80OC until use.
Protein concentration in microsomal fraction
was determined by Lowry protein assay (26).
Chromatographic conditions
Chromatographic separation was performed on
a Kinetex (2.6 µm, PFP, 100 , 100 ◊ 3 mm,
Phenomenex, Torrance, CA, USA) analytical col-
umn using UltiMate 3000 UPLC system (Dionex,
USA). The mobile phase consisted of acetonitrile
containing 0.1% formic acid (eluent A) and water
containing 0.1% formic acid (eluent B). At the flow
rate of 500 µL/min, the amount of eluent A
increased lineary from 20 to 95% in 2 min, main-
tained by 95% for 6 min, then returned to 20% in 3
min, and was left to equilibrate for 6 min. The total
run time was 15 min.
LC/MS/MS conditions
The analyzed compounds were detected using
TSQ Quantum Ultra triple quadrupole mass spec-
trometer (Thermo Scientific, Waltham, MA, USA).
Heated electrospray ionization (H-ESI) was used
both in the positive and negative (for 6-hydroxy-
chlorzoxazone) modes. The selected reaction moni-
toring transitions and collision energies optimized
for each metabolite and internal standard are listed
in Table 1. The mass spectrometric conditions were
as follows: needle voltage 4020 V, vaporizer tem-
perature 250OC, sheath gas (nitrogen) pressure 30
psi, auxiliary gas (nitrogen) pressure 10 psi, capil-
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lary temperature 370OC. The argon pressure in the
collision cell was approximately 2 mTorr.
Standard and quality control samples
Stock solutions of metabolites of model sub-
strates and dextrophan used as an internal standard
(IS) were prepared at concentration of 0.5 mg/mL in
methanol. Working solutions for calibration stan-
dards were prepared by diluting the stocks in water
to the concentrations of 0.125, 0.3125, 0.625, 1.25,
3.25, 6.25, 9.375, 12.5 and 25 µg/mL of each analyte
in cocktail, and 0.125, 0.375, 1.125, 10, 22.5 µg/mL
for quality control samples. Dextrophan was diluted
in acetone : acetonitrile mixture (1 : 1, v/v) to a final
concentration of 250 ng/mL. 
Calibration samples were made at 10, 25, 50,
100, 250, 500, 750, 1000 and 2000 ng/mL for 4í-
hydroxymephenytoin and 4-hydroxytolbutamide;
50, 100, 250, 500, 750, 1000 and 2000 ng/mL for 1-
hydoxybufuralol and 25, 50, 100, 250, 500, 750,
1000 and 2000 ng/mL for the rest of analyzed
metabolites. 
Quality control (QC) samples were prepared at
30, 800 and 1800 ng/mL for 4í-hydroxymepheny-
toin and 4-hydroxytolbutamide, and 90, 800 and
1800 ng/mL for other substances. Calibration stan-
dards and quality control samples were prepared by
spiking 40 µL of working solution of cocktail of
analytes with blank microsomal medium (without
NADPH). In the next step, to stop the reaction, the
mixture of acetonitrile : acetone (1 : 1, v/v) with
internal standard was added. After vortex mixing
and cooling down on ice, samples were centrifuged
at 15 000 ◊ g for 15 min, and supernatant was ana-
lyzed using LC/MS/MS method.
Method validation
Validation of the method was carried out
according to the FDA and EMA bioanalytical
method validation guidelines (27, 28) with respect
to the linearity, selectivity, precision, accuracy,
recovery, limit of detection, limit of quantification,
matrix effect and post-preparative stability.
Selectivity is the ability of the analytical
method for separation and quantification of the ana-
lyte in the presence of other compounds in the sam-
ple. It was assessed by studying peak interference
from six independent sources of microsomes.
Calibration curves were constructed using
seven to nine calibration standards and fitted by a
weighted least-squares linear regression. To assess
linearity, deviations of the back calculated concen-
Table 1. Selected reaction monitoring parameters for quantified analytes.
Analyte Q1 [m/z] Q3 [m/z] CE [V]
Acetaminophen 152 110 14
4-Hydroxytolbutamide 287 89 38
4í-Hydroxymephenytoin 235 150 19
1-Hydroxybufuralol 278 186 14
6ñHydroxychlorzoksazone 180 120 20
1í-Hydroksymidazolam 342 324 21
4í-Hydroxymidazolam 342 297 24
Dextrophan (IS) 258 157 38  
Table 2. Linear ranges, determination coefficients, limits of detection and limits of quantification for selected compounds.
ACP 6-OH-CH 4-OH-MP 1-OH-BF 4-OH-TB 1-OH-MZ 4-OH-MZ
Liner range [ng/mL] 25-2000 25-2000 10-2000 50-2000 10-2000 25-2000 25-2000
Determination 
coefficient (r2)
0.9994 0.9995 0.9916 0.9908 0.9965 0.9974 0.9983
LOD [ng/mL] 0.1 1 0.05 0.01 0.01 0.025 0.01
LLOQ [ng/mL] 25 ± 2.8 25 ± 2.8 10 ± 1.3 50 ± 5.9 10 ± 0.5 25 ± 3.0 25 ± 3.1
ACP - acetaminophen; 6-OH-CH - 6-hydroxychlorzoxazone; 4-OH-MP - 4í-hydroxymephenytoin;  1-OH-BF - 1-hydroxybufuralol; 4-OH-
TB - 4-hydroxytolbutamide; 1-OH-MZ - 1í-hydroxymidazolam; 4-OH-MZ - 4í-hydroxymidazolam. 
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trations were set at ±15% of the nominal ones,
except of the LLOQ, when a deviation of ±20% was
permitted.
Inter- and intra-batch precision and accuracy of
the assay were verified for three concentrations of
QC samples. Six replicates of sample were analyzed
on the same day to determine the intra-day precision
and accuracy, and on each of two separate days to
determine inter-day precision and accuracy. The
mean values of precision should be within 15% of
the actual value, except of LLOQ, where it should
not deviate more than 20%. The accuracy deter-
mined at each concentration level should not exceed
85-115%, except of LLOQ, where it should not
exceed 80-120%. 
The limit of detection (LOD) was defined as
the concentration that generates a signal-to-noise
ratio of 3, whereas the limit of quantification
(LLOQ) was determined as the lowest concentration
of the analytes in the sample, which can be quanti-
fied with precision lower than 20%, and an accura-
cy between 80% and 120%.
The stability of samples in autosampler batch
was assessed by reanalyzing extracted QC samples
kept under the autosampler conditions (10OC) for 24
h. An acceptable stability was defined if the initial
loss of concentration was below 15%. 
Recovery and absolute matrix effect were
assessed at three concentrations of QC samples by
comparing the peak areas of 6 runs at each concen-
tration for the neat solutions of analytes and the
standard solutions spiked before and after protein
precipitation. Recovery was calculated by dividing
the mean peak area of standards spiked before
extraction by mean peak area of standards spiked
after extraction. 
Figure 1. Fragmentation mass spectra of selected metabolites with purposed fragmentation pathways: 4-hydroxytolbutamide (A), aceta-
minophen (B), 1-hydroxybufuralol (C), 6-hydroxychlorzoxasone (D), 1-hydroxymidazolam (E) and 4-hydroxymidazolam (F)
Validation of LC/MS/MS method for assessment of the in vitro activity of... 1093
The matrix effect was evaluated by comparing
the mean peak area of the analyte spiked post extrac-
tion to the mean peak of its neat solutions. The
absolute matrix effect was defined as (1 - signal of
post-extracted spiked sample/signal of pure solution)
◊ 100%. The relative matrix effect was also estimated
according to the work of Matuszewski (29) by assess-
ing the variability of standard line slopes expressed as
coefficient of variation. The precision of the method
should not exceed 4%, and then is considered to be
reliable and free from the relative matrix effect.
Inhibition study
To the total volume (0.5 mL) of incubation
mixture of rat liver microsomes (1 mg/mL) added
0.1 M phosphate buffer (pH 7.4), 10 mM MgCl2, 1
mM NADPH and substrates cocktail in concentra-
tions near their Km values: phenacetin - 7.5 µg/mL,
tolbutamide - 2.5 µg/mL, bufuralol - 12.5 µg/mL,
chlorzoxazone - 15 µg/mL and midazolam - 7.5
µg/mL. To the incubation mixture ketoconazole was
added in the concentration range of 0.3 to 37.5 µM.
Mixtures were preincubated for 5 min at +37OC in a
shaking water bath (OLS 200, Grant Instruments,
Cambridge, UK). The reaction was initiated by addi-
tion of NADPH (cofactor of metabolic reaction).
Following a 10 min incubation, the reaction was ter-
minated with 500 µL of ice cold mixture of acetoni-
trile : acetone (1 : 1, v/v) containing dextrophan as
an internal standard (250 ng/mL). Samples were
subsequently cooled on ice for 20 min to precipitate
the proteins, and then centrifuged at approximately
15 000 ◊ g for 15 min at 4OC. The supernatant (200
µL) was transferred to vials, and a volume of 20 µL
was injected onto the analytical column. 
CYP-mediated activities in the presence of
ketoconazole were expressed as a percentage of the
corresponding control values. A sigmoidal shaped
curve were fitted to the data and the IC50 values for
ketoconazole were calculated by fitting the Hill
equation to the data using non-linear regression of
the plot of percent control activity versus concentra-
tion of ketoconazole using Prism (GraphPad
Software, Version 6). The enzymes activities in the
presence of ketoconazole were compared with the
control samples without addition of ketoconazole.
Figure 2. Extracted SRM chromatograms of simultaneous analysis of seven metabolites of model substrates and IS in calibration standard
sample. Abbreviations see Table 2 
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RESULTS AND DISCUSSION
Method development
Metabolism studies of new compounds that
occur with the participation of enzymes require sim-
ple, quick, sensitive and reproducible analytical
methods. The aim of this work was to develop and
validate a simple and reliable LC/MS/MS method,
which can be used to determine simultaneously
seven metabolites of specific substrates of selected
CYP450 isoenzymes in rat liver microsomes.
Animal models are widely used to predict
kinetics and toxicity of drugs in human, and
cytochrome P450 enzymes are mainly involved in
the metabolism of drugs both in human and rodents.
The three families: CYP1, CYP2 and CYP3 play a
significant role in drug biotransformation (30).
Differences between e.g., human and rat enzymes
concern mostly individual genes, while not only
families but also subfamilies are common. Major
isoenzymes of CYP450 in human liver are: CYP
1A2, CYP 2B6, CYP 2C8, CYP 2C9, CYP 2D6 and
CYP 3A4/5, while in rat are: CYP 1A1, CYP 1A2,
CYP 2B1, CYP 2C6, CYP 2C11, CYP 2D1/2, CYP
3A1/2 and CYP 4A1. Enzymes CYP 2C and CYP
3A appear to be the most abundant cytochromes
P450 in rat and human liver, respectively (31). 
Most of the described in the literature experi-
ments deal with human microsomes, while there are
a lot of work performed on rat microsomes, because
rats are the most commonly used model in preclini-
cal studies (6, 32-34). Zhang et al. (6) studied
phenacetin, tolbutamide, mephenytoin, dextro-
methorphan and midazolam metabolism incubated
Figure 3. The activity of selected  isoenzymes after incubation of model substrates of CYP450 with ketoconazole in rat liver microsomes.
Data are shown as the mean ± SD, n = 3. 1-OH-MZ - 1'-hydroxymidazolam; 4-OH-MZ - 4'-hydroxymidazolam 
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individually and in cocktail form with rat micro-
somes and no significant differences were observed.
Phenacetin and tolbutamide metabolism in rat liver
microsomes were studied by Jurica et al. (32).
Coctail assay was used to study herb-drug interac-
tion in rat microsomes by Xia et al. (33). Recently,
comparison between human and rat microsomal
CIME cocktail assay was verified by Videau et al.
(34). 
In presented work, the model substrates of
selected isoenzymes of CYP450 were added in the
form of cocktail to rat microsomes. Substrates were
selected on the basis of a number of literature
reports describing the metabolism of drugs in rats
(30, 31, 35ñ37) and the EMA guideline describes
probe substances, which can be used for evaluation
of cytochrome P450 activity in human (38). The fol-
lowing model substrates were selected: phenacetin
for CYP 1A2, tolbutamide for CYP 2C9, S-
mephenytoin for CYP 2C19, bufuralol for CYP
2D6, chlorzoxazone for CYP 2E1 and midazolam
for CYP 3A4. Fragmentation mass spectra of select-
ed metabolites and proposed fragmentation path-
ways are shown in Figure 1.
The analytes were at first detected in full scan
mass spectrum and then fragmented to product ions
to ascertain their pseudo-molecular ions and to
select product ions used in SRM mode. Except of
chlorzoxazone and its metabolite, which responded
better in negative ionization mode, all other sub-
stances were quantified in positive ion mode.
A simple protein precipitation method was
used for sample purification and different precipita-
tion mixtures were verified. The results showed that
the most efficient way was precipitation using a
mixture of acetonitile and acetone (1 : 1, v/v). 
Table 3. Intra- and inter-day precision and accuracy of the method.
ACP 6-OH-CH 4-OH-MP 1-OH-BF 4-OH-TB 1-OH-MZ 4-OH-MZ
LLOQ 11.1 10.4 13.0 19.5 4.5 12.6 13.0
Intra-day
QC low 3.2 8.8 4.0 7.5 4.4 7.1 5.1
precision
QC medium 11.0 7.6 3.4 2.7 2.5 1.7 1.0
(RSD%)
QC high 8.4 6.5 3.8 2.1 3.0 3.5 2.7
LLOQ 13.9 12.0 12.0 7.5 3.2 5.4 6.6
Inter-day
QC low 5.6 7.5 7.4 14.9 6.1 6.3 4.1
precision
QC medium 11.7 5.9 11.0 4.0 7.5 4.7 3.0
(RSD%)
QC high 10.8 5.4 7.5 3.5 3.5 4.0 2.4
LLOQ 118.7 106.3 103.1 83.7 107.0 97.2 96.5
Accuracy QC low 102.9 95.5 106.0 113.6 99.8 98.2 109.2
(%) QC medium 103.3 98.1 104.6 106.7 99.8 103.8 102.7
QC high 107.4 93.0 99.7 99.6 97.6 105.4 98.2
Abbreviations see Table 2.
Table 4. Extraction recovery and absolute matrix effect of the method.
ACP 6-OH-CH 4-OH-MP 1-OH-BF 4-OH-TB 1-OH-MZ 4-OH-MZ
QC low 85.4 92.0 68.4 83.5 74.1 79.4 82.1
Recovery
QC medium 70.5 91.1 68.3 86.4 74.3 84.8 83.0   
[%]
QC high 75.3 94.8 71.4 89.0 78.9 91.1 90.6   
Mean ± SD 77.1 ± 7.6 92.6 ± 1.9 69.4 ± 1.8 86.3 ± 2.8 75.8 ± 2.7 85.1 ± 5.9 85.2 ± 4.7
Absolute 
QC low 65.0 16.5 8.9 -23.7 20.2 12.3 -14.8%
matrix QC medium 61.9 17.9 14.0 5.2 22.7 -5.4 0.2
effect [%]
QC high 60.1 10.2 10.1 4.0 20.8 -6.8 2.0
Mean ± SD 62.3 ± 2.5 14.9 ± 4.1 11.0 ± 2.7 -4.8 ± 16.4 21.2 ± 1.3 0.03 ± 10.6 -4.2 ± 1.2
Abbreviations see Table 2.
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Method validation
Selectivity and linearity 
No interference was found at the retention time
of the analytes and the IS during analysis of blank
microsomes from six independent sources (signal-
to-noise ratio < 9). Extracted SRM chromatograms
of seven metabolites of model substrates and IS in
calibration standard sample are shown in Figure 2. 
The assay was linear over the concentration
range of 10-2000 ng/mL for 4í-hydroxymepheny-
toin and 1-hydroxytolbutamide, 50-2000 ng/mL
for 1-hydroxybufuralol, and 25-2000 ng/mL for the
rest of the analyzed metabolites. Linear ranges,
determination coefficients, LOD and LLOQ values
are shown in Table 2. The best linear fit of the cal-
ibration curve for each analyte was obtained using
a weighting factor 1/x. Precision and accuracy of
the LLOQ met the requirements both of FDA and
EMA guidelines, RSD < 20% and 80-120%,
respectively. 
Precission and accuracy
For all quantified metabolites, the intra-day
coefficients of variation were less than 11% for low,
medium and high QC concentrations, and less than
20% for LLOQ. The inter-day data were also repro-
ducible with CV less than 12% for prepared QC
samples, and less than 14% for LLOQ. The study
shows good accuracy: 93-114% for low, medium
and high QC concentrations, and 83-119% for
LLOQ level. Precision and accuracy data for each of
the analytes are summarized in Table 3.
Recovery and matrix effect
Table 4 shows the results of recovery and
absolute matrix effect for all selected analytes. A
simple precipitation method used in this study yield-
ed a mean recovery greater than 69% for all ana-
lytes. The extraction recovery was noticed to be con-
sistent for each analyte over the entire QC concen-
tration range, what can indicate that extraction effi-
ciency of the method is reliable over the studied
concentration. 
The mean values of absolute matrix effect
ranged from 0.03 to 62.3%, and the higher matrix
effect was observed for acetaminophen (62.3%) but
even so, the calibration curve covered the expected
concentration range. To confirm the reliability of
this method, the relative matrix effect was studied.
Coefficients of variation of calibration curve slopes
for compounds studied were less than 1.8% (Table
5), and according to Matuszewski indications (29),
the method was free from the relative matrix effect
liability.
Stability study
Analyzed aliquots were stable in autosampler
batch in 10OC for at least 24 h. The mean values of
the calculated concentrations were within 94-113%
and therefore acceptable (Table 6). Consequently,
extracts from sample incubation may be placed in
autosampler rack for up to 24 h.
Application of the method
The method was used to assess the strength of
inhibition of ketoconazole on selected CYP450
isoenzymes. The incubation curves are shown in
Figure 3 and determined IC50 values for ketocona-
zole are listed in Table 7. The results showed that
ketoconazole had the most potent inhibitory effect
on CYP 3A4 (IC50 = 1 µM), but also suppressed
activity of CYP 1A2 (IC50 = 4.4 µM), CYP 2E1 (IC50
= 8.1 µM) and CYP 2C9 (IC50 = 23.5 µM), whereas
the activity of CYP 2D6 was not changed.
Many researchers found that antifungal azoles
can inhibit the activity of several cytochrome P450
Table 5. Individual and mean values of standard line slopes for analytes studied.
Slope of the calibration curve
ACP 6-OH-CH 4-OH-MP 1-OH-BF 4-OH-TB 1-OH-MZ 4-OH-MZ
0.00048 7.8309E-06 0.000155 0.00275 0.00043 0.0046 0.00147
0.00048 7.8867 E-06 0.00015 0.00286 0.00044 0.0049 0.00148
0.0005 8.2371 E-06 0.000153 0.00291 0.00043 0.00478 0.00152
0.00049 8.3464 E-06 0.00015 0.00288 0.00043 0.00468 0.00153
0.00051 8.4954 E-06 0.000149 0.00286 0.00047 0.00461 0.00147
0.00052 8.2371 E-06 0.000139 0.00288 0.00042 0.00491 0.00148
Mean 0.000496 8.17227 E-06 0.000149 0.00285 0.000436 0.004747 0.001492
CV [%] 3.3 3.2 3.7 1.9 4.0 2.9 1.8
Abbreviations see Table 2.
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isoenzymes. In the work (39), Paine et al. demon-
strated the inhibition of intestinal CYP 1A2 by keto-
conazole. Suppression of tolbutamide hydroxylase
(reaction catalyzed by CYP 2C9) by azoles in in
vitro experiments was studied by Back et al. (40).
They found that ketoconazole inhibited CYP 2C9 in
human microsomes with IC50 = 16.5 µM. The effect
of non-selective cytochrome P450 inhibitors such as
1-aminobenzotriazole, SKF-525A and ketoconazole
on human cytochrome P450 isoenzymes was studied
by Emoto et al. (41). They found that ketoconazole
exerts weak inhibitory potential on CYP 1A2 activ-
ity (Ki = 120 µM), CYP 2C competitive inhibition
(Ki = 7.9 µM for CYP 2C9 and Ki = 6.9 µM for CYP
2C19), mixted inhibition on CYP 2D6 activity (Ki =
12 µM) and CYP 2E1 activity (Ki = 41 µM) and
competitive inhibition on CYP 3A4 (Ki = 0.02 µM). 
The influence of ketoconazole on amiodarone
metabolism both in human and rat microsomes was
studied by Elsherbiny et al. (42). Interestingly, in rat
liver microsomes ketoconazole exerted higher
inhibitory potential on CYP 2D enzymes than on
CYP 3A family. The human isoenzymes most inhib-
ited by ketoconazole were CYP 1A1, CYP 3A4,
CYP 2D6 and CYP 1A2, respectively. The working
groups of Kobayashi et al. (43) and Eagling et al.
(44) studied the effect of different inhibitors on
cytochrome P450 activity in rats and showed that
ketoconazole is not specific CYP 3A inhibitor, but it
can suppress the activity of other isoenzymes. Only
in one in vivo work, it was shown that ketoconazole
had no effect on cytochrome P450 activity in rats
(45). 
Despite the use in presented studies different
substrates and different substrate concentrations it
can be seen that ketoconazole has the strongest
inhibitory potential on CYP3A4 but this drug is also
strong inhibitor of CYP1A2 and CYP2E1 and mod-
erate inhibitor of CYP2C9. Presented data are gen-
erally in good agreement with earlier cited studies
and confirmed that ketoconazole should not be con-
sider as a selective CYP 3A4 inhibitor in rat liver
microsomes.
CONCLUSIONS
A sensitive and an accurate LC/MS/MS
method has been developed for the simultaneous
evaluation of the activities of six cytochrome P450
izoenzymes in rat liver microsomes. The method
was successfully validated following FDA and
EMA guidelines that ensures the acceptability of its
performance and the reliability of analytical results.
The applied screening cocktail was verified with
ketoconazole, a known CYP450 enzyme inhibitor.
The resulting method can be used as a first and rapid
screening of new compounds, drug candidates using
rat liver microsomes. 
Table 6. Autosampler stability data for analytes studied.
Stability of analytes [%]
ACP 6-OH-CH 4-OH-MP 1-OH-BF 4-OH-TB 1-OH-MZ 4-OH-MZ
QC low 103.2 95.7 101.3 100.4 109.5 102.2 94.9 
QC medium 111.6 106.4 105.7 106.3 112.6 105.0 94.4
QC high 111.2 102.7 104.7 103.6 104.4 105.2 95.7
Abbreviations see Table 2.
Table 7. The influence of ketoconazole on the inhibition of selected isoenzymes.
Isoenzyme Substrate Metabolite Ketoconazole
IC50 [µM]
CYP 1A2 Phenacetin Acetaminophen 4.40 ± 0.29
CYP 2C9 Tolbutamide 4-Hydroxytolbutamide 23.5 ± 0.05
CYP 2D6 Bufuralol 1-Hydroxybufuralol ó-
CYP 2E1 Chlorzoxazone 6-Hydroxychlorzoxazone 8.10 ± 0.041
CYP 3A4
Midazolam 1í-Hydroxymidazolam 1.51 ± 0.024
Midazolam 4í-Hydroxymidazolam 1.02 ± 0.027
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